MAAC Pharma is an emerging research-focused pharmaceutical company dedicated to delivering high-quality, affordable, and innovative healthcare solutions. We work with a mission to create better treatment options for patients and support improved global health.
Our Investigational Medicinal Products (IMP) are being prescribed through Early Patient access schemes in the UK, USA, Europe, and Australia.
Our treatments, provided to patients through an early access scheme, yield real-world data on safety and efficacy, complementing our clinical trials.
Our European research hub is a powerhouse of innovation, where new ideas are nurtured into medical treatments. This facility supports our drug development lifecycle, from concept to commercial launch.
Addressing unmet medical needs by integrating Polypharmacology and Nanotechnology.
To become a globally recognized Biopharmaceutical
company, providing accessible,
impactful solutions in healthcare.
To research and develop innovative
treatments, focusing on global health
challenges, with an emphasis
on immunology and neurology.
Regularly introducing new novel treatments based of Polypharmacology and Nanotechnology.
Ensuring our treatments are accessible worldwide.
Aiming to set new benchmarks in the Biopharmaceutical industry with multidiscipline innovative treatments.